CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, ...

The first phase of construction is beginning on a new $2.19 billion health care, training and research facility for the University of Nebraska Medical Center and Nebraska Medicine, its clinical ...

Scale-up is a common problem encountered in all forms of development across industries, and oral solid dose manufacturing ...

GI Alliance and Iterative Health have formed a strategic partnership to expand access to clinical trials across ...

Clinical trials improve care and access to novel treatments for advanced gastrointestinal cancers, says Dr. Michael Pishvaian ...

REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule MEK 1/2 inhibitor. The platform analyzed cellular models of APC gene loss-the root cause of FAP-to identify compounds ...

Visit https://www.apbioinc.com/en/ for more information about AP Biosciences and its pipeline of next-generation cancer therapies.

Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

Researchers at the University of California San Diego School of Medicine have identified a potential new treatment, an ...

New research reveals that MRI distance measures may more accurately predict cognitive decline during the preclinical phase of ...

In 2025, newly-designed clinical trials for people with cancer are providing new options and hope for patients and their ...

Trials are used to test potential medicines, treatments or procedures. The National Institutes for Health define a clinical ...